In the present study, we aimed to explore the association between patient factors, tumor PD-L1 expression and molecular profile and the development of thyroid irAEs in NSCLC patients treated with PD-1 or PD-L1 inhibitors. Here, PDCD1 is linked to non-small cell lung carcinoma.